Advertisement
UK markets close in 1 hour 49 minutes
  • FTSE 100

    8,125.81
    +46.95 (+0.58%)
     
  • FTSE 250

    19,789.82
    +187.84 (+0.96%)
     
  • AIM

    755.21
    +2.09 (+0.28%)
     
  • GBP/EUR

    1.1673
    +0.0017 (+0.14%)
     
  • GBP/USD

    1.2506
    -0.0005 (-0.04%)
     
  • Bitcoin GBP

    51,193.50
    +646.10 (+1.28%)
     
  • CMC Crypto 200

    1,377.63
    -18.91 (-1.35%)
     
  • S&P 500

    5,085.00
    +36.58 (+0.72%)
     
  • DOW

    38,164.54
    +78.74 (+0.21%)
     
  • CRUDE OIL

    84.21
    +0.64 (+0.77%)
     
  • GOLD FUTURES

    2,352.60
    +10.10 (+0.43%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,084.73
    +167.45 (+0.93%)
     
  • CAC 40

    8,064.47
    +47.82 (+0.60%)
     

Teva Pharmaceutical Focusing on Per Product Operating Profits

Teva Pharmaceutical Focusing on Per Product Operating Profits

Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has been focused on maximizing its revenues through its market-leading generics portfolio. The company, however, has been facing stiff competition in the generics market from Mylan (MYL), Gilead Sciences (GILD), and Pfizer (PFE), which has resulted in price erosion in the generics market.